Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Human HVEM/TNFRSF14 Protein

Human HVEM/TNFRSF14 Protein

CAT#: ICP-A026

Inquiry

Overview Specification

Species	Human
Tag	C-His
Expression Systems	Expi293
Keywords	Human; C-His; Expi293

Synonyms	CD270; CD40-like protein; HVEM; LIGHTR; ATAR; TNFRSF14; TR2
Background	Herpesvirus entry mediator (HVEM), also known as tumor necrosis factor receptor superfamily member 14 (TNFRSF14), is a human cell surface receptor of the TNF-receptor superfamily. Two TNF superfamily ligands lymphotoxin α (TNF-β) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM and initiate positive signaling.
Source	Recombinant Human HVEM/TNFRSF14 Protein is expressed from Expi293 with His tag at the C-terminal. It contains Leu39-Val202.
Molecular Weight	The protein has a predicted MW of 18.5 kDa. Due to glycosylation, the protein migrates to 32-48 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	>95% as determined by Tris-Bis PAGE. >95% as determined by HPLC.
Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80℃ for 12 months as supplied from the date of receipt. -20 to -80℃ for 3-6 months in an unopened state after reconstitution. 2-8℃ for 2-7 days after reconstitution.
Notes	Recommend to aliquot the protein into smaller quantities for optimal storage. Please avoid freeze-thaw cycles.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Online Inquiry

Alfa Cytology provides its clients with one-stop solutions to accelerate therapeutic discovery and development of brain tumors.

By Disease

Craniopharyngioma

Schwannoma (neuroma)

Pituitary Tumors

Choroid Plexus Tumors

By Molecule Type

Small Molecule Drug

Therapeutic Antibody

Immune Cell Therapy

Oncolytic Virotherapy

Vaccine Development

Contact Us

Copyright © 2024 Alfa Cytology. All rights reserved.